Trademark: 90796130
Word
THERORNA
Status
Registered
Status Code
700
Status Date
Tuesday, September 12, 2023
Serial Number
90796130
Registration Number
7159975
Registration Date
Tuesday, September 12, 2023
Mark Type
5000
Filing Date
Friday, June 25, 2021
Published for Opposition
Tuesday, June 27, 2023

Trademark Owner History
THERORNA Inc - Original Registrant

Classifications
5 Pharmaceutical preparations for human biomedicine, namely, pharmaceutical preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; vaccines; drugs for medical purposes, namely, medicinal preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; opotherapy preparations; serotherapeutic medicines, namely, medical immune serums used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; biological preparations for medical purposes, namely, biological preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; medicines for human purposes, namely, medicines used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and new coronavirus vaccine; chemical preparations for medical purposes, namely, medicinal preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and new coronavirus vaccine; adjuvants for medical purposes; Blood for medical purposes; nutraceutical preparations for therapeutic or medical purposes; immunostimulants; Medical cell function activating drugs, namely, medicinal preparations used for protein replacement therapy, cardiovascular therapy, liver disease therapy, cancer therapy, respiratory disease therapy, infectious disease therapy, neurological disease therapy, and for use as a new coronavirus vaccine; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; tumor suppressing agents; Anti-sarcoma preparations; cytostatics for medical purposes; Pharmaceutical products for the prevention and treatment of cancer; all the foregoing using circular ribonucleic acid (RNA)

Trademark Events
Sep 12, 2023
Notice Of Registration Confirmation Emailed
Sep 12, 2023
Registered-Principal Register
Jun 27, 2023
Official Gazette Publication Confirmation E-Mailed
Jun 27, 2023
Published For Opposition
Jun 7, 2023
Notification Of Notice Of Publication E-Mailed
May 19, 2023
Law Office Publication Review Completed
May 12, 2023
Approved For Pub - Principal Register
May 12, 2023
Examiner's Amendment Entered
May 12, 2023
Notification Of Examiners Amendment E-Mailed
May 12, 2023
Examiners Amendment E-Mailed
May 12, 2023
Examiners Amendment -Written
Nov 1, 2022
Teas/Email Correspondence Entered
Nov 1, 2022
Correspondence Received In Law Office
Nov 1, 2022
Teas/Email Correspondence Entered
Sep 19, 2022
Correspondence Received In Law Office
Nov 1, 2022
Assigned To Lie
Sep 19, 2022
Teas Response To Office Action Received
Sep 19, 2022
Teas Response To Office Action Received
Mar 18, 2022
Notification Of Non-Final Action E-Mailed
Mar 18, 2022
Non-Final Action E-Mailed
Mar 18, 2022
Non-Final Action Written
Mar 16, 2022
Assigned To Examiner
Sep 9, 2021
New Application Office Supplied Data Entered
Jun 29, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24